{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:07:17Z","timestamp":1762520837498},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.1053\/beha.2002.0222","type":"journal-article","created":{"date-parts":[[2002,12,11]],"date-time":"2002-12-11T01:48:30Z","timestamp":1039571310000},"page":"449-465","source":"Crossref","is-referenced-by-count":10,"title":["Antibody-based therapy of non-Hodgkin's lymphoma"],"prefix":"10.1053","volume":"15","author":[{"given":"James M.","family":"Foran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/beha.2002.0222_RF1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1098\/rspl.1899.0121","article-title":"On immunity with special reference to cell life","volume":"66","author":"Ehrlich","year":"1900","journal-title":"Proceedings of the Royal Society of London (Biology)"},{"key":"10.1053\/beha.2002.0222_RF2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/blood.V31.1.104.104","article-title":"Infusion of isologous immune plasma in chronic lymphocytic leukemia","volume":"31","author":"Laszlo","year":"1968","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/bjc.1972.21","article-title":"Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer","volume":"26","author":"Currie","year":"1972","journal-title":"British Journal of Cancer"},{"key":"10.1053\/beha.2002.0222_RF4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"10.1053\/beha.2002.0222_RF5","first-page":"147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen","volume":"40","author":"Nadler","year":"1980","journal-title":"Cancer Research"},{"key":"10.1053\/beha.2002.0222_RF6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody","volume":"306","author":"Miller","year":"1982","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2002.0222_RF7","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJM198506273122602","article-title":"Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies","volume":"312","author":"Meeker","year":"1985","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2002.0222_RF8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V80.4.863.863","article-title":"Monoclonal antibody-based therapies of leukemia and lymphoma","volume":"80","author":"Grossbard","year":"1992","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"10.1053\/beha.2002.0222_RF10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF11","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"Journal of Immunology"},{"key":"10.1053\/beha.2002.0222_RF12","first-page":"4906","article-title":"Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies","volume":"49","author":"Press","year":"1989","journal-title":"Cancer Research"},{"key":"10.1053\/beha.2002.0222_RF13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunology Today"},{"key":"10.1053\/beha.2002.0222_RF14","first-page":"767a","article-title":"High levels of soluble CD20 (sCD20) in patients with non-Hodgkin's lymphoma (NHL): correlation with clinical behavior and contrast with patients with Hodgkin's disease (HD)","volume":"98","author":"Vose","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","article-title":"Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas","volume":"69","author":"Press","year":"1987","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (Anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunp\u00e4\u00e4","year":"2000","journal-title":"Scandinavian Journal of Immunology"},{"key":"10.1053\/beha.2002.0222_RF17","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF18","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumour cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin's lymphoma","volume":"98","author":"Weng","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF19","first-page":"268a","article-title":"Extended rituximab therapy is highly active and facilitates hematological recovery in patients with lymphoplasmacytic lympohoma (Waldenstr\u00f6ms macroglobulinemia)","volume":"21","author":"Treon","year":"2002","journal-title":"Proceedings of ASCO"},{"key":"10.1053\/beha.2002.0222_RF20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/cimm.2000.1693","article-title":"Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines","volume":"204","author":"Flieger","year":"2000","journal-title":"Cellular Immunology"},{"key":"10.1053\/beha.2002.0222_RF21","first-page":"338a","article-title":"Effector cell-mediated mechanisms play the dominant role in the cytotoxicity of rituximab on human peripheral blood B-cells from normal donors and patients with CLL","volume":"96","author":"Voso","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.leu.2402424","article-title":"Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils","volume":"16","author":"van der Kolk","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0222_RF23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"4","author":"Clynes","year":"2000","journal-title":"Nature Medicine"},{"key":"10.1053\/beha.2002.0222_RF24","first-page":"179b","article-title":"Identification of a novel polymorphism in the human FCGR2B gene: correlation with response to rituximab treatment in patients with follicular lymphoma","volume":"96","author":"Fitzgibbon","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF27","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell lymphocytic leukemia","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF28","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V99.1.67","article-title":"Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma","volume":"99","author":"Ansell","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03019.x","article-title":"Loss of CD20 expression following treatment with rituximab (chimeric monoclonal anti-CD20): a retrospective cohort analysis","volume":"114","author":"Foran","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0222_RF31","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF32","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunology and Immunotherapy"},{"key":"10.1053\/beha.2002.0222_RF33","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF34","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF35","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF36","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2141.2000.01965.x","article-title":"A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response","volume":"109","author":"Foran","year":"2000","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0222_RF38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","article-title":"Rituximab: ongoing and future clinical development","volume":"29","author":"Grillo-Lopez","year":"2002","journal-title":"Seminars in Oncology"},{"key":"10.1053\/beha.2002.0222_RF39","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","article-title":"Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma","volume":"95","author":"Hainsworth","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF40","first-page":"38a","article-title":"Maintenance treatment with 2-monthly rituximab after standard weekly x 4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma","volume":"13","author":"Ghielmini","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1053\/beha.2002.0222_RF41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF43","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1023\/A:1008350208019","article-title":"Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity","volume":"10","author":"Byrd","year":"1999","journal-title":"Annals of Oncology"},{"key":"10.1053\/beha.2002.0222_RF44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002371-200105000-00012","article-title":"CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia","volume":"24","author":"Treon","year":"2001","journal-title":"Journal of Immunotherapy"},{"key":"10.1053\/beha.2002.0222_RF45","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstr\u00f6ms macroglobulinemia with rituximab","volume":"9","author":"Dimopoulos","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF46","first-page":"267a","article-title":"IELSG phase II study of rituximab in MALT lymphoma: final results","author":"Conconi","year":"2002","journal-title":"Proceedings of ASCO"},{"key":"10.1053\/beha.2002.0222_RF47","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF48","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF49","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF50","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance","volume":"17","author":"Byrd","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF51","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1182\/blood.V98.6.1991","article-title":"Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment","volume":"98","author":"Kunzmann","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF52","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Annals of Oncology"},{"key":"10.1053\/beha.2002.0222_RF53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/15258160151135088","article-title":"Rituximab in the treatment of refractory follicular lymphoma \u2013 six doses are better than four","volume":"10","author":"Avil\u00e9s","year":"2001","journal-title":"Journal of Hematotherapy and Stem Cell Research"},{"key":"10.1053\/beha.2002.0222_RF54","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF55","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biotherapy & Radiopharmacology"},{"key":"10.1053\/beha.2002.0222_RF57","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF58","first-page":"601a","article-title":"Progression free survival after six years median follow-up of the first clinical trial of rituximab\/CHOP chemoimmunotherapy","volume":"98","author":"Czuczman","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF59","first-page":"601a","article-title":"Phase II study of rituximab plus fludarabine in patients (pts) with low-grade lymphoma (LGL): final report","volume":"98","author":"Czuczman","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF60","first-page":"772a","article-title":"Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia (CLL) patients: results from CALGB 9712","volume":"98 (supplement 1)","author":"Byrd","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/sonc.2002.30144","article-title":"Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone","volume":"29","author":"Sarris","year":"2002","journal-title":"Seminars in Oncology"},{"key":"10.1053\/beha.2002.0222_RF62","first-page":"37","article-title":"Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma","volume":"27","author":"McLaughlin","year":"2000","journal-title":"Seminars in Oncology"},{"key":"10.1053\/beha.2002.0222_RF63","first-page":"771a","article-title":"Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia","volume":"98","author":"Wierda","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF64","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF65","first-page":"38a","article-title":"Multicenter phase II study with rituximab treatment for follicular and mantle cell lymphoma after high\u2013dose therapy and autologous blood stem cell transplantation","volume":"13","author":"Brugger","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1053\/beha.2002.0222_RF66","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1023\/A:1008309405678","article-title":"Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response","volume":"11","author":"Foran","year":"2000","journal-title":"Annals of Oncology"},{"key":"10.1053\/beha.2002.0222_RF67","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF68","first-page":"726a","article-title":"Mantle cell lymphoma (MCL) -- high rates of complete remission (CR) and prolonged failure-free survival (FFS) with rituxan-hyperCVAD (R-HCVAD) without stem cell transplant (SCT)","volume":"98","author":"Romaguera","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF69","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2002.0222_RF72","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF73","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF74","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood.V99.6.2245","article-title":"Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia","volume":"99","author":"Kennedy","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF75","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1200\/JCO.1998.16.10.3257","article-title":"CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study","volume":"16","author":"Lundin","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF76","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF77","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","article-title":"In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation","volume":"96","author":"Kottaridis","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF78","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF79","first-page":"92a","article-title":"Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): phase I\/II trial results","volume":"94","author":"Leonard","year":"1999","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF80","first-page":"38a","article-title":"High complete response rate following epratuzumab (anti-CD22) and rituximab (anti-CD20) combination antibody therapy in follicular non-Hodgkin's lymphoma","volume":"13","author":"Leonard","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1053\/beha.2002.0222_RF81","first-page":"606a","article-title":"A phase II study of RemitogenTM (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic or marginal zone\/MALT B-cell lymphoma","volume":"98","author":"Link","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF82","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2002.0222_RF83","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [I1311]anti-B1 (anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2002.0222_RF84","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma","volume":"19","author":"Kaminski","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/beha.2002.0222_RF85","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0222_RF86","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"Journal of Clinical Oncology"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692602902227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692602902227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T07:16:58Z","timestamp":1704698218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692602902227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["S1521692602902227"],"URL":"https:\/\/doi.org\/10.1053\/beha.2002.0222","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}